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SUMMARY
Th2-biased inﬂammation with eosinophilia and IgE production is a hallmark of helminth infections. It is pronounced in
hyperreactive onchocerciasis patients (‘sowda’ or ‘local form’), who eﬃciently kill microﬁlariae resulting in severe
dermatitis and lymphadenitis. In contrast, hyporeactive patients (‘generalised form’) tolerate high microﬁlarial loads. This
is thought to be mediated by regulatory CD4
+ T cells and macrophages producing suppressive cytokines such as IL-10 and
transforming growth factor-beta (TGF-β). We investigated whether hyperreactivity was reﬂected by lower local TGF-β
production, analysing stable latent TGF-β1 expression in onchocercomas, lymph nodes and skin from hyperreactive and
hyporeactive patients by immunohistochemistry. TGF-β expression was compared with that of IgE, IgG1, IgG4, and the
antigen-presenting, CD4
+ T cell-inducing MHC class II molecule HLA-DR. TGF-β was weakly and less frequently
expressed by various cell types in onchocercomas, skin and lymph nodes from hyperreactive compared to hyporeactive
patients. This applied to reactions around living and dead adult worms as well as dead microﬁlariae. Antigen-presenting
cells strongly expressed HLA-DR in both forms, but their numbers were reduced in hyperreactive nodules. Plasma cells
produced more IgE and IgG1, but less of the anti-inﬂammatory antibody IgG4 in hyperreactive onchocercomas. In
conclusion, hyperreactivityis linked withreducedlocal expressionof TGF-β, HLA-DRand IgG4,whichmight contribute
to the insuﬃcient down-regulation of inﬂammation via TGF-β- and HLA-DR-induced regulatory lymphocytes.
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INTRODUCTION
In sub-Saharan Africa, Yemen and Latin America an
estimated 37 million people suﬀer from a chronic
infection with the ﬁlarial nematode Onchocerca
volvulus that aﬀects skin, the lymphatic system and
eyes (river blindness). Non-productive adult worms
barely elicit immune responses and disease. The
pathology is caused by millions of microﬁlariae (mf)
that are released from adult worms in subcutaneous
onchocercomas and which migrate to the skin and in
smaller numbers to other organs. In hyperendemic
foci tens or hundreds of thousands of mf die every
day in many patients. Murdoch et al. (1993) devel-
oped a classiﬁcation scheme for onchocerciasis skin
lesions and a WHO Expert Committee (1995) rec-
ommended its use. Skin and lymphatic lesions were
diﬀerentiated into ‘generalised’ and ‘local’ forms of
onchocerciasis (WHO, 1995) and these terms were
also used for the polar forms of the immunological
spectrum of onchocerciasis. To avoid misunder-
standing, since hyporeactive onchodermatitis is also
often ‘local’ and hyperreactive onchodermatitis may
be extended, here we will only use the terms
‘hyporeactive’ (synonym for ‘generalised form’) and
‘hyperreactive’ (synonym for ‘local or localised form’
or ‘sowda’) for the polar forms of the immunological
spectrum (WHO, 1995).
The objective of this study was to investigate
whether the immunosuppressive cytokine TGF-β
playsaroleintheweakimmunosuppression observed
in hyperreactive patients, based on our observation
that O. volvulus elicits strong local host cell TGF-β
production in highly infected and immunosup-
pressed hyporeactive patients (Korten et al. 2010).
The cellular and humoral immunological defence
reactions to mf, induced by ﬁlarial antigens, are
usually strong in primarily infected individuals,
killing the mf and often causing dermatitis (WHO,
1987, 1995; Cooper et al. 2001; Brattig, 2004). In
hypoendemic areas the worms die after 5–12 years.
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acquired and the reactivity decreases with increasing
worm burdens in most patients. They develop the
hyporeactive, immunosuppressed form of the infec-
tion, tolerating high mf loads and reacting only
against damaged or treated mf and adult worms, but
they do not kill viable mf (Ottesen, 1995; Brattig,
2004). However, they kill most of the newly acquired
infective larvae (WHO, 1995; Schulz-Key and
Soboslay, 2000). In contrast, a minority of patients
develop a chronic hyperreactive form of infection
with a sustained strong immunological defence
reaction that kills mf. This leads to low mf loads of
less than 10mf/mg skin (mostly less than 1 mf/mg)
and severe dermal and lymphatic disease (see below
in the Materials and Methods section; Büttner et al.
1982; Connor et al. 1983; WHO, 1987). Usually, also
the chronic hyperreactivity ends when the adult
ﬁlariae die. Or, as we observed between 1978 and
1989 in Liberia, the hyperreactive form may change
to the hyporeactive form, when the worm load
increases after a few years (Gallin, 1987; Büttner,
unpublished data). Between the two polar forms
there are many patients with intermediate forms,
including most primary infections, who are able to
kill mf, but present a low degree of hyporesponsive-
ness. The immunological spectrum of pathology
hints at mechanisms based on genetic pre-disposition
and immune modulatory factors that lead to variable
host reactivity to the worm antigens (King and
Nutman, 1991; Hoerauf et al. 2002, 2005; Brattig,
2004; Timmann et al. 2008). Hyperreactivity is char-
acterized by a strong local and systemic Th2-type
biased immune reaction, that correlates with skin and
lymph node pathology and comprises elevated serum
and tissue IgE, eosinophilia, mastocytosis, increased
activated CD4
+ T helper cells, dense inﬁltrates with
T cells, B cells, plasma cells, and extensive ﬁbrous
tissue generation in onchocercomas (Brattig et al.
1987; Korten et al. 1998; Timmann et al. 2003;
Brattig, 2004). In hyporeactive onchocerciasis, these
Th2-driven inﬂammatory responses are weaker
and mixed with a suppressive Tr1/Th3 response.
Antigen-speciﬁc and non-speciﬁc immunosuppres-
sion is mediated by CD4
+ regulatory T (Treg) cells
and macrophages, which produce suppressive cyto-
kines such as IL-10 and TGF-β (Kilian and Nielsen,
1989; Doetze et al. 2000; Hoerauf et al. 2005;L iet al.
2006; Taylor et al. 2006; Korten et al. 2008).
To study whether local TGF-β expression reﬂects
the spectrum of the polar immune states, we analysed
TGF-β1 (denoted as TGF-β hereafter) expression
in host cells of onchocercomas, lymph nodes and
skin from hyperreactive compared to hyporeactive
patients. We further analysed TGF-β expression in
relation to the expression of the immunoglobulins
IgE, IgG1, IgG4 and the antigen-presenting mol-
ecule HLA-DR, which induces and activates cognate
Th2 and Th3 CD4
+ T cells (Muixí et al. 2008).
MATERIALS AND METHODS
Diagnosis of hyperreactive patients
The diagnosis of hyperreactive onchocerciasis was
based on the criteria used previously (Büttner et al.
1982; Albiez et al. 1985; Gallin, 1987; Darge and
Büttner, 1995). The following criteria had to be
fulﬁlled by all patients of this study. (1) The disease
had to exist at least for a year. Usually it had existed
for several years. (2) The patients had to be mf
carriersprovenbydetectionofmfinskinsnipsorbya
positive Mazzotti test. The mf density had to be less
than 10 mf/mg of skin. In Liberia, on all patients a
topical Mazzotti test with diethylcarbamazine lotion
had been applied on 2 areas of 20×20 cm, one on sick
and oneon rather healthyskin (Kilian,1988;Fig. 1in
Darge and Büttner, 1995), because the skin snips
were often negative. A Mazzotti test was considered
as positive, when a reaction with at least 20 fresh
papules and usually more than 100 fresh papules was
observed after 1 or 2 days. All patients in our study
had shown a positive test. (3) All patients had
presented signs of an acute or chronic papular
onchodermatitis (APOD or CPOD as described by
Murdoch et al. 1993; Murdoch, 2010) and com-
plained of strong pruritus, conﬁrmed by scratch
marks. (4) An onchocercoma with living or dead
female ﬁlariae had been excised for histology.
Further criteria were the presence of a dark-coloured
skin area, typical asymmetry of skin lesions, licheni-
ﬁed onchodermatitis (LOD by Murdoch et al. 1993),
and enlarged regionallymph nodesto asize of 2–6c m
or more (stage 2 of Murdoch et al. 1993). The
patients had usually shown several of these further
signs. Untreated hyperreactive patients had shown
eosinophilia of the blood, usually of more than 10%.
The average values of the study patients were 24±
14% and 1600±1566 eosinophils/μl blood, respect-
ively. Except for Yemen all examined hyporeactive
patients had lived in highly endemic onchocerciasis
foci. They were adult individuals with long-standing
infections carrying high loads of nodules and more
than 40 mf/mg skin.
Onchocercomas, lymph nodes and skin from patients
Sixty-fouronchocercomasfrom50untreatedLiberian
and Yemenite patients with hyperreactive onchocer-
ciasis were selected from previous studies (references
in Table 1). Fourty-nine of these nodules were
stained for TGF-β and compared with 82 onchocer-
comas from 82 untreated patients with the hypo-
reactive form of the disease. The total number of
hyporeactive nodules, stained for TGF-β and other
markers, was 130 from 94 patients. Six hyporeactive
and 3 hyperreactive patients had received 1–3 stan-
dard doses of ivermectin (IVM) during mass or
individual treatment and were nodulectomized be-
tween 1 day and 2 months later. One onchocercoma
36 S. Korten and otherswas derived from a German boy, who became infec-
ted in Cameroon, developed hyperreactive dermatitis
and was treated with 2 standard doses of 0·15 mg/kg
IVM 4 and 6 months prior to nodulectomy. Only a
subgroup of these nodules was stained with diﬀerent
Abs depending on ﬁxation and needed information.
The patients in this study were HIV-negative. The
HIV infection was excluded by testing or, in Liberia,
Mali, Burkina Faso, and Yemen by epidemiology,
sincenodulectomy hadtakenplacebeforetheonsetof
the HIV1 epidemic in the investigated onchocerciasis
foci.
Fig. 1. Immunohistological comparison of TGF-β and HLA-DR expression by macrophages and CD3
+ T cells in
onchocercomas from untreated hyporeactive and hyperreactive patients in Liberia and Ghana. (A-B) Nodule centre with
strong (hyporeactive) and weak (hyperreactive) TGF-β expression (arrows) around older female worms. (C-D) Details of
TGF-β
high (hyporeactive) and TGF-β
low (hyperreactive) nuclei and cytoplasm of macrophages (arrow) adjacent to
female worms (f), while a small giant cell, attached to the cuticle, is negative (*). (E-H) Serial sections with strong
(hyporeactive) and weak or negative (hyperreactive) TGF-β (E-F) and HLA-DR (G-H) expression (arrows) mainly in
macrophages adjacent to productive female worms and an attached HLA-DR
+ giant cell (*). Immune cells further
distant from the worm are HLA-DR
+ (arrowhead in H), whereas they are TGF-β-positive (F) and macrophages
adjacent to the worm are HLA-DR-negative (H). (J-M) Moribund or dead mf in a nodular microgranuloma being
attacked by macrophages strongly (hyporeactive) or faintly (hyperreactive) expressing TGF-β or HLA-DR (arrows).
(K+M) are serial sections. (N-Q) Mainly CD3
+ T lymphocytes express TGF-β strongly in a nodule from a
hyporeactive and weakly in a nodule from a hyperreactive patient. (N+P and O+Q) are serial sections.
(P+Q) CD3-staining. Scale bars=50 µm.
37 TGF-beta in hyperreactive onchocerciasisThe Ethics Commission of the Medical Board,
Hamburg, had approved nodulectomies for research
purposes. Nodulectomies were also, generally, sup-
ported by the World Health Organization (WHO,
1987). The design of the diﬀerent drug studies had
been approved by the authorities and by ethic
committees of the respective African countries (see
references). The procedures used were in accordance
with the Declaration of Helsinki (1975, and its
revisions in 1983, 2000 and 2002, where applicable).
The nodulectomies were performed under aseptic
conditions and local anaesthesia as described (Albiez
et al. 1988a). Among the onchocercomas excised by
us, and those that were sent to us by other groups
were usually up to 5% lymph nodes, which had been
misdiagnosed asonchocercomas(Albiezetal.1988a).
In nodule series from patients after long IVM mass
treatment, vector control and those with hyperreac-
tive infection the percentages were higher because
these patients have fewer onchocercomas. In total,
16 lymph nodes from 7 hyperreactive and 9 hypo-
reactive patients were included in this study, 11 from
untreated and 5 from IVM-treated patients (for
references see Table 1). From 22 untreated hypo-
reactive and 17 untreated hyperreactive patients, skin
samples were taken from the wound edge adjacent to
the excised onchocercomas (Table 1).
Immunohistochemistry
Onchocercomas, lymph nodes and skin were ﬁxed in
4% buﬀered formaldehyde or in 80% ethanol and
embedded in paraﬃn using standard methods. The
number, sex, productivity, and vitality of the worms
were determined morphologically (Korten et al.
2008). As a rich cellular inﬁltrate is dependent on
the presence of at least one mf-producing female
worm or on dead worms (Wildenburg et al. 1998;
Korten et al. 2008), and host TGF-β expression is
induced by nulliparous, previously or presently pro-
ductiveor dead femaleworms in hyporeactiveoncho-
cercomas (Korten et al. 2010), nodules with at least
one such female worm were used for this immuno-
logical comparison between the two forms of oncho-
cerciasis. Young nulliparous female worms were
present in larger nodules from hyporeactive patients.
Male worms were present in many nodules with
females; in this nodule series males did not occur
alone.
For staining of latent TGF-β1, only formaldehyde-
ﬁxed nodules could be used because the anti-
serum did not stain ethanol-ﬁxed host tissues (albeit
ethanol-ﬁxed worm tissue, Korten et al. 2009).
Therefore not all nodules examined could be stained
with anti-TGF-β serum. The sections were pre-
treated with an endogenous peroxidase-blocking
agent as part of the anti-goat HRP-AEC Cell &
Tissue Staining Kit (horseradish peroxidase-3-
amino-9-ethyl-carbazole;R&DSystems,Wiesbaden,
Germany). As described previously (Korten et al.
2009, 2010) latent TGF-β1 was labelled with a
speciﬁc polyclonal IgG antibody produced with
recombinant goat anti-human latency peptide/
protein (LAP; R&D Systems), diluted 1:200 and for
non-ﬁlarial samples 1:10 in 1% FCS/TBS. Titration
experiments for optimal dilutions of the primary
antibody and positive control staining were per-
formed on known LAP
+ prostate carcinoma samples
(Steineretal.1994).Non-speciﬁcgoatserumwiththe
same IgG concentration was applied for negative
Table 1. Untreated and ivermectin-treated hypo- and hyperreactive onchocerciasis patients and numbers






















47 None 61 (46) 4 17 Liberia (Albiez et al. 1985)
3 3 (3) 2 0 Yemen (Büttner et al. 1982)
1 2×0·15mg/kg 1 (0) 0 0 Cameroon (Korten et al. 1998)
2 1×0·15mg/kg 2 (2) 1 0 Liberia (Darge and Büttner, 1995)
Hyporeactive
25 None 35 (13) 1 2 Ghana (Hoerauf et al. 2003)
30 42 (32) 3 20 Liberia (Albiez et al. 1988b)
12 17 (17) 0 0 Burkina F.
b (Büttner et al. 1988)
13 16 (16) 0 0 Mali (Büttner et al. 1988)
14 20 (4) 0 0 Uganda (Fischer et al. 1993)
1 0 1 0 Yemen (Büttner et al. 1982)
91 –3×0·15mg/kg 12 (6) 0 0 Uganda (Fischer et al. 1993)
2 1×0·15mg/kg 2 (2) 4 0 Liberia (Albiez et al. 1988b)
a 49 nodules from 50 untreated hyperreactive patients and 82 nodules from 82 untreated hyporeactive patients
were examined for TGF-β, the other nodules for other markers as outlined in the Materials and methods section;
b Burkina Faso.
38 S. Korten and otherscontrols. Pre-diluted biotinylated anti-goat mAb
servedassecondaryantibody.Forvisualization,slides
were incubated with streptavidin-HRP and devel-
oped with the brown chromogenic substrate AEC or
with the streptavidin-biotin Super Sensitive Detec-
tion Kit (BioGenex, San Ramon, CA, USA) and
Vector Red Substrate Kit (Vector Labs, Burlingame,
CA, USA). When an aﬃnity-puriﬁed goat anti-
human LAP antibody and a mouse monoclonal
antibody (mAb) against TGF-β became available, a
number of sections were stained to conﬁrm the
speciﬁcity of the labelling using the ﬁrst antibodies
(not shown).
TGF-β-positive or -negative cell types were
determined morphologically and on the basis of a
similar location of cells stained with the following
diﬀerentiation markers on serial sections. Mainly
mAbs were applied (DakoCytomation, Hamburg,
Germany): anti-CD68 (clone PG-M1) for mature
macrophages, anti-L1 protein (synonymous with
clone MAC387) for immature macrophages, anti-
MHC class II molecule HLA-DR(clone TAL.1B5),
and anti-mast cell tryptase (clone AA1); polyclonal
antibodies against CD3 to detect all T lymphocytes,
and against IgE, IgG1 and IgG4. For these anti-
bodies the APAAP technique was applied according
to the protocol from DakoCytomation, using sec-
ondary rabbit anti-mouse and mouse anti-rabbit
Abs and Fast Red TR salt (Sigma, Deisenhofen,
Germany). Haematoxylin (Merck, Darmstadt,
Germany) served as counter stain.
Not all nodules could be stained with all anti-
bodies. Some nodules had only been stained with the
diﬀerentiation markers mentioned above and with
others speciﬁc for eosinophils, neutrophils, alpha
1-antichymotrypsin, and prostaglandin E2, which
are not mentioned here. Forty-nine nodules from
hyperreactive and 82 nodules from hyporeactive
patients were stained for TGF-β and a subgroup of
these also for the above-mentioned diﬀerentiation
markers using consecutive sections.
Statistical analysis
For the analysis of diﬀerence between nodules from
hyperreactive patients with low intensity of TGF-β
staining and nodules from hyporeactive patients
with strong TGF-β staining the chi square test
was applied (http://math.hws.edu/javamath/ryan/
ChiSquare.html), assuming P<0·05 to be a signiﬁ-
cant diﬀerence.
RESULTS
Hyperreactive patients show reduced TGF-β expression
Onchocercomas with productive or previously pro-
ductive older worms revealed a much stronger
expression of TGF-β1 (denoted as TGF-β hereafter)
and more frequently positive cells around and be-
tween sections of the adult worms, when patients had
the hyporeactive form of onchocerciasis (Fig. 1A, C
and E) in contrast to the hyperreactive form (Fig. 1B,
D and F). This was observed in numerous mature
CD68
+ and L1 protein
+ (data not shown, see
Discussion section) macrophages forming a wall
adjacent to the cuticle of the adult worms in both
polar forms (Fig. 1A–F). Few TGF-β
+ macrophages
and numerous TGF-β
+ lymphocytes occurred more
distant from the adult worms in the nodule centre,
but again with reduced expression levels in hyper-
reactive nodules (Fig. 1F). Similarly, macrophages
attacking dead mf expressed more TGF-β in nodules
from hyporeactive (Fig. 1J) than in those from
hyperreactive patients (Fig. 1K). CD3
+ T cells
(Fig. 1P and Q) in perivascular inﬁltrates strongly
expressed TGF-β in hyporeactive(Fig. 1N), but very
weakly and less frequently in hyperreactive oncho-
cercomas (Fig. 1O). Mast cells and ﬁbrocytes were
also weaker TGF-β
+ in hyperreactive onchocercomas
(data not shown).
The diﬀerence in TGF-β expression was always
obvious. In hyporeactive nodules, the stained
immune cells were mainly strongly or moderately
TGF-β positive. In hyperreactive nodules the stain-
ing of the macrophages varied mainly from negative
to weakly positive, seldom to moderately positive,
but the cells were never as strongly stained as the
positive cells in hyporeactive nodules. Figures 1–3
clearly demonstrate the diﬀerent intensities in the
two groups of patients. These ﬁgures are represen-
tative; they were not selected for the intensity of
TGF-β staining. The diﬀerence between the 49
hyperreactive and the 82 hyporeactive TGF-β
stained nodules is signiﬁcant, when comparing the
weak and strong expression for the total nodule
numbers between the two groups (P<0·001, chi
square test).
A quantiﬁcation and statistical analysis of the
frequency of TGF-β stained cells appeared not to
be adequate since most nodules from hyperreactive
patients contained many more immune cells than
those from hyporeactive patients (Büttner and Racz,
1983) and weighed between 1·7 and 8·3 g in contrast
tomosthyporeactivenodules weighinglessthan1·3 g
(Albiez et al. 1988a). Despite this high number of
immune cells elicited by only one or two female
worms in hyperreactive nodules, most of these
immune cells were only weakly or not TGF-β
stained. This diﬀerence in cellular inﬁltration was
also evident between the large lymph nodes of
hyperreactive patients and the ﬁbrotic nodes from
hyporeactive patients (Connor et al. 1983;R a c zet al.
1983) and between the onchodermatitis skin from
hyperreactive patients and the often clinically only
scarcely altered skin in the hyporeactive group
(Connor et al. 1983).
39 TGF-beta in hyperreactive onchocerciasisFurthermore, the proportions of TGF-β negative
or positive young L1 protein positive macrophages
and TGF-β negative prostaglandin E2 expressing
macrophages varied between the two groups, and in
hyporeactive nodules strongly TGF-β
+ cells were so
abundant and often densely packed, that it would
have been diﬃcult to quantify them in contrast
to clear-cut populations of FOXP3+ lymphocytes
(Korten et al. 2008).
Stronger HLA-DR expression in hyporeactive than
in hyperreactive patients
Since all antigen-speciﬁcC D 4
+ T cells, including
T helper and Treg cells, are induced and activated
via MHC class II molecules such as HLA-DR on
antigen-presenting cells, we compared HLA-DR
expression in relation to TGF-β between the two
forms of onchocerciasis. HLA-DR expression was
equally strong in both forms, but HLA-DR
+ cells
occurred more abundantly in hyporeactive nodules
(Fig. 1G and H). This was particularly striking for
the completely HLA-DR-negative macrophages in
the cell walls adjacent to the cuticle of productive
females in hyperreactive nodules (Fig. 1H) in con-
trast to the homogenously HLA-DR
+ macrophages
adjacent to females in hyporeactive onchocercomas
(Fig.1G).HLA-DR
+macrophages andlymphocytes
inﬁltrated the ﬁbrous tissue at some distance from
the adult worms in hypo- and hyperreactive nodules
(Fig. 1H). But the expression was stronger in hypo-
reactive nodules. Central and subcapsular inﬁltrates
were densely packed with strongly HLA-DR
+ cells.
In contrast to the cells adjacent to adult worms,
strongly HLA-DR expressing macrophages closely
Fig. 2. Immunohistological comparison of TGF-β and immunoglobulin production by plasma cells and macrophages in
onchocercomas from hypo- and hyperreactive patients in Liberia and Uganda. (A-B) Plasma cells (arrow) strongly
(hyporeactive) and faintly (hyperreactive) expressing TGF-β. Untreated patients. (C) Weakly TGF-β
+ macrophages
(arrows) attached to a productive female worm (f) 2 months after IVM. Hyperreactive. (D) Only TGF-β
+ endothelia
(arrowhead) are seen but nearly no immune cells near to a moribund female worm harbouring a pleomorphic neoplasm
(tu) ﬁlling the entire pseudocoeloma cavity (Duke et al. 2002; Brattig et al. 2010). Hyperreactive. (E) Weakly TGF-β
+
macrophages (arrow) around a microgranuloma (arrowhead) with a dead mf in a nodule from a hyperreactive patient 2
months after IVM treatment. (F) A dead mf coated by IgG1 (arrow) in a nodule from a hyperreactive German child
after IVM. (G-H) Weakly (hyporeactive, 48 h after IVM) and strongly (hyperreactive, untreated) IgG1 producing
plasma cells (arrows). TGF-β (J-K) or HLA-DR (L-M) (arrows) faintly (hyporeactive) and strongly (hyperreactive)
IgE producing plasma cells (arrows) in perivascular inﬁltrates. Untreated patients. (L-M) Many (hyporeactive) and few
(hyperreactive) IgG4 producing plasma cells (arrows) in nodules with productive female worms (f); 2–3 days after
IVM treatment. Scale bars=20µm (A, B, E); 50 µm (C-D, F-M).
40 S. Korten and othersencircled degenerated mf in both forms, but accu-
mulated in higher numbers in the hyporeactive
infection (Fig. 1L and M).
In summary, these results show that TGF-β
expression positively correlates with HLA-DR ex-
pression, particularly in the cellular reaction around
adult worms and less around mf.
Plasma cells expressed more IgE and IgG1, but less
IgG4 in hyperreactive patients
CD20
+ B cells, including plasma cells, were
abundantly found in all onchocercomas with mf-
producing and/or degenerating adult worms. Plasma
cells often accumulated in lymphocyte inﬁltrates and
produced more TGF-β in hyporeactive (Fig. 2A)
than in hyperreactive onchocercomas (Fig. 2B).
Many plasma cells produced IgE or IgG1 in both
polar forms, but strongly IgG1 or IgE expressing
plasma cells occurred more frequently in hyperreac-
tive (Fig. 2F, H, K) than in hyporeactive nodules
(Fig. 2G and J). Inversely, IgG4 was abundantly
expressed in hyporeactive (Fig. 2L) and scarcely in
hyperreactive nodules (Fig. 2M).
Insummary,weakTGF-βandIgG4 expressionby
plasma cells correlated with hyperreactivity, inver-
sely to IgE and IgG1.
TGF-β in nodules from IVM-treated patients
After IVM treatment the macrophages attached to
the female worms did not or only weakly expressed
TGF-β in hyperreactive patients (Fig. 2C). In
hyperreactive patients, this weak TGF-β expression
was also seen around dead or moribund adult worms
such as those with neoplasms (Fig. 2D). Degenerated
mf were encircled by macrophages, eosinophils,
some CD3
+ T lymphocytes and mast cells forming
microgranulomas in nodules from IVM-treated
hyperreactive patients, and these cells were also
only weakly TGF-β positive (Fig. 2E).
Hyperreactivity imparts reduced TGF-β expression
in lymph nodes and skin
In contrast to stronger expression in hyporeactive
patients (Fig. 3A and C) many lymphocytes (Fig. 3B)
and macrophages (Fig. 3D) showed less TGF-β in
lymph nodes of hyperreactive patients. Likewise,
numerous endothelia of small blood vessels in lymph
nodes were TGF-β
+ in both polar forms, but they
were less strongly stained in hyperreactive patients
(Fig. 3E and F). Furthermore, TGF-β expression
was observed in numerous cells in small inﬂamma-
tory inﬁltrates in the dermis as well as in Langerhans
cells in the basal layer of the epidermis (Fig. 3G
and H). The expression was higher in the skin from
hyporeactive than in skin from hyperreactive patients
(Fig. 3G and H). But the diﬀerence appeared to be
less than observed in onchocercomas and lymph
nodes from hyporeactive patients.
Fig. 3. Immunohistological comparison of TGF-β
expression in lymph nodes (A-F) and skin (G-H) from
hypo- and hyperreactive patients in Liberia and Uganda.
(A-B) Strong (hyporeactive) and faint TGF-β expression
(hyperreactive) in lymphocytes (arrows) adjacent to
remnants of nearly resorbed mf (arrowhead). Untreated
patients. (C-D) Strong (hyporeactive) and faint TGF-β
expression (hyperreactive) in macrophages (arrows); 1 day
or 5 weeks after IVM treatment. (E-F) Strongly
(hyporeactive) TGF-β
+ and faintly (hyperreactive)
TGF-β expressing endothelia of blood vessels; 1 day or
5 weeks after IVM treatment. (G-H) Skin from untreated
patients. (G) Macrophages and lymphocytes with varying
degrees of TGF-β expression (arrow) accumulating in a
dermal inﬁltrate and strongly TGF-β
+ Langerhans cells
in the epidermis (arrowhead; hyporeactive). (H) A
similar accumulation of less strongly TGF-β expressing
cells in a dermal inﬁltrate and of Langerhans cells in the
epidermis (arrowhead) of a hyperreactive patient. Scale
bars=50µm.
41 TGF-beta in hyperreactive onchocerciasisIn summary, a similar weak TGF-β expression
occurred in lymph nodes and skin as in onchocerco-
mas from hyperreactive patients.
DISCUSSION
Comparing the in situ expression of latent TGF-β
in onchocercomas, lymph nodes and skin between
hyperreactive and hyporeactive patients, we show
that all three organs from hyperreactive patients
expressed lower levels of TGF-β and reduced
numbers of TGF-β
+ cells despite a strong inﬂam-
matory inﬁltrate. As TGF-β was less intensely and
less frequentlyexpressedbutpresentinhyperreactive
nodules, this indicates the ability of these patients
to express TGF-β. It might reﬂect that TGF-β
expression is up-regulated and latent TGF-β (LAP)
released also in hyperreactive patients, but more
quickly cleaved into active TGF-β, e.g. by proteases
such as metalloproteinases (Taylor, 2009; Korten
et al. 2010). Alternatively, LAP could bind to cell-
surface proteins such as integrins undergoing a
conformational change and releasing active TGF-β,
whichwasnot detected by the TGF-βantibody used.
An argument against this is that active TGF-β bind-
ing to receptors of eﬀector cells should lead to
suppression of hyperreactivity, which is not the
case. Another explanation might be that cellular pro-
duction could reach a point of exhaustion in hyper-
reactivity in response to a strong and constant
inﬂammation overwhelming any regulatory eﬀect.
The hyperreactive response in primary infections
of all non-endemic and endemic infected individuals
indicates that any initial TGF-β response to inﬂam-
mation is too weak to suppress and needs further
signals to develop. We presume that ﬁlarial and not
endobacterial antigens provide such signals, since
depletion of Wolbachia did not alter TGF-β ex-
pression (Korten et al. 2010). Furthermore, only in
hyporeactive patients did ﬁlarial antigens from adult,
predominantly female, worms elicit a substantial
TGF-β expression, which rises with the ﬁrst mf
productionandissustainedinnon-productivephases
and during worm degeneration, death and resorption
(Korten et al. 2010). This local TGF-β production
increases with worm burden, suppressing defensive
Th2 responses and counterbalancing immunopath-
ology. Since TGF-β induces CD4
+ Treg cells, a
growing worm load promotes the generation of
O. volvulus-speciﬁc as well as non-speciﬁcT r e g
cells found in onchocercomas (Hoerauf et al. 2005;
Korten et al. 2008).
One explanation for the low TGF-β expression in
hyperreactive tissues could be that chronically in-
fected hyperreactive patients cannot mount a suf-
ﬁcient TGF-β response during the hyperreactive
phase due to a pre-disposing genetic factor. The Ov1
locus on chromosome 2p is linked to mf loads in the
skin and resistance in onchocerciasis, close to a region
for asthma, also a Th2-driven condition (Timmann
et al. 2008). Moreover, since protein kinase C epsilon
isafunctional candidategene ofOv1(Timmannetal.
2008) and protein kinase C epsilon mediates in-
creased TGF-β production in mice (Koyanagi et al.
2007) this locus might be associated with the
observed diﬀerences in TGF-β1 expression.
Therefore, hyperreactive patients may have devel-
oped and sustained a strong Th2 response from
the beginning of infection that quickly killed and
removed mf. We assume that this prohibited
the development of TGF-β-mediated tolerance in
hypoendemic regions. However, in meso- and hyper-
endemic areas, tolerance eventually overcomes
hyperreactivity due to higher transmission pressure
and the increasing worm load. In onchocercomas
from untreated and IVM-treated hyperreactive
patients, degenerated mf were encircled by macro-
phages, eosinophils, CD3
+ T cells and some mast
cells (Korten et al. 1998), but these cells were TGF-
β-negative or faintly TGF-β
+ in contrast to hypo-
reactive nodules (for the hyporeactive form only, see
Korten et al. 2010). This and the similarly weak
TGF-β reaction around dead adult worms showed
the independence of the low TGF-β expression from
the worm status, reinforcing the concept of pre-
disposition. This is also supported by a study
showing that TGF-β release into the circulation is
genetically controlled and correlates with the occur-
rence and severity of certain diseases (Grainger et al.
1999). In addition, hyperreactive patients from both
Ghana and Guinea were shown to have a pre-
disposition for increased IL-13 signalling and thus,
stronger Th2 responses (Hoerauf et al. 2005). Since
TGF-β suppresses Th1/2 cell proliferation and
diﬀerentiation (Li et al. 2006), the lack of TGF-β
could promote local and systemic cell proliferation,
which is increased in patients with severe and chronic
skin pathology (Timmann et al. 2003).
TGF-β not only suppresses immune cells, but can
also promote ﬁbrous tissue generation and ﬁbrosis.
Themuchstrongerﬁbroustissuereactionaroundone
or two femaleworms inthe presence of scarceTGF-β
in hyperreactive nodules may be an argument against
such a role of TGF-β in hyperreactive patients.
However, the increased ﬁbrosis seen in lymph nodes
and skin of older hyporeactive patients with long-
standing infections could partially result from their
high TGF-β production apart from immune com-
plexes of O. volvulus mf antigens, which cause
inﬂammation and formation of additional laminae
of vascular walls and perivascular ﬁbrosis (Connor
etal.1983).SinceweobservedTGF-β
+macrophages
and lymphocytes in the hyporeactive lymph nodes,
such TGF-β expression could reﬂect suppressive
macrophage populations in the regional lymph
nodes. In line with this, a spreading of alternatively
activated macrophages from the site of infection to
the regional lymph nodes with the onset of mf release
42 S. Korten and othersis observed in murine ﬁlarial infection (Taylor et al.
2006). Brattig et al.( 2009) reported a lower pro-
duction of prostaglandin E2 and TGF-β by macro-
phages in onchocercomas from hyperreactive than in
those from hyporeactive patients, and the production
of these two compounds in diﬀerent suppressive
macrophage subtypes.
Plasma cells were a major source of TGF-β apart
from macrophages, T cells, mast cells, endothelial
cells, and ﬁbrocytes in hyporeactive (Korten et al.
2010) and hyperreactive onchocercomas, but the
expression was less in the hyperreactive form. The
enhanced IgE and IgG1, but scarce IgG4 expression
by plasma cells in hyperreactive onchocercomas
is in line with reports on the inverse role of these
immunoglobulins (Brattig et al. 1994; Ottesen,
1995; Brattig, 2004). The production of IgG4,
a predominantly blocking, anti-inﬂammatory and
tolerance-inducing antibody (van der Neut
Kolfschoten et al. 2007; Aalberse et al. 2009)b yB
cells is induced by IL-10 and TGF-β producing Tr1
and natural Treg cells in onchocerciasis (Satoguina
et al. 2008). Therefore, our ﬁnding of simultaneously
high TGF-β and IgG4 expression by plasma cells
in hyporeactive infections is concordant with this
notion. This supports the assumption of parallel
expressionbyseveralplasmacellsorpossiblythesame
plasma cells being regulatory B cells (Lund, 2008).
Brattig et al. (1987) showed increased HLA-DR
expression by peripheral blood leukocytes in hyper-
reactive patients. In contrast, we found substantial
numbers of positive cells, but decreased local ex-
pression intensities in hyperreactive onchocercomas
compared to strong and more abundant expression
in hyporeactive ones. This might indicate a local
exhaustion of expression in chronic hyperreactivity.
However, since HLA-DR molecules induce and
activate antigen-speciﬁc CD4
+ T cells in general,
and can be expressed by activated Treg cells (Muixí
etal.2008;BattagliaandRoncarolo,2009),thestrong
expression in hyporeactive patients could also lead to
the generation of cognate CD4
+ Treg cells and
not only of CD4
+ helper cells. An association of
HLA-DR molecules with the clinical spectrum of
onchocerciasis has been reported by Meyer et al.
(1994). A clear association exists between HLA-DR
expression and autoimmune diseases such as rheu-
matoid arthritis and thyroid autoimmune disease
(Muixí et al. 2008). In both, the complex of the
presented peptide with the MHC class II molecule
HLA-DR can be recognized by cognate eﬀector and
regulatory T cells promoting either autoreactivity or
tolerance.
In conclusion, this study showed an association
between chronic Th2-mediated hyperreactivity in
onchocerciasis and reduced local expression of the
suppressive cytokine TGF-β by various cell types,
primarily macrophages, T cells and plasma cells.
This low TGF-β expression was found in all
infection sites irrespective of the worm status or the
presence of mf. It was further linked with reduced
HLA-DR expression. Therefore, we suggest a new
tolerance-promoting rolefor MHC class II-mediated
immune responses in conjunction with local TGF-β
expression, which develops in hyporeactive, but not
in hyperreactive patients. This might be important
not only for the understanding of hyperreactivity to
ﬁlarial nematodes, but also for other Th2-mediated
diseases such as allergy and asthma.
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